Ranitidine HCl is one group of H2-blockers that is normally used for the therapy of upper digestive tract. Ranitidine absorption occurs only in the gastric and initial part of intestine. In addition, ranitidine also undergoes metabolism in the colon, therefore it has a low bioavailability. According to that, a drug delivery system that maintains preparation in the gastric to increase absorption in the gastric in order to increase bioavailability is needed. The tablet was made using wet granulation method with HPMC K15M as the matrix by adding ethyl cellulose 10 cps to inhibit the release of ranitidine. This is because as a drug, HPMC K15M will increase the release of ranitidine HCl. The tablet produced was evaluated for its floating property and release using the medium of HCl 0.1N at 370C for 8 hours using type II dissolution test equipment. The test results proved that the tablet produced has a good floating property and with a decrease in the concentration of ethyl cellulose, it will increase the release of ranitidine HCl.
Cite this article:
Unun Faiz Su'udiyah, Sugiyartono. The Effect of Ethyl Cellulose 10 Cps on the floating Characteristic and Ranitidine HCL release from floating Tablet (using HPMC K15M Matrix). Research J. Pharm. and Tech. 2021; 14(2):735-740. doi: 10.5958/0974-360X.2021.00128.1
Unun Faiz Su'udiyah, Sugiyartono. The Effect of Ethyl Cellulose 10 Cps on the floating Characteristic and Ranitidine HCL release from floating Tablet (using HPMC K15M Matrix). Research J. Pharm. and Tech. 2021; 14(2):735-740. doi: 10.5958/0974-360X.2021.00128.1 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-2-24
1. Sreekanth Y. Formulation and Evaluation of Nizatiding Floatince Table. KK College of Pharmacy, Chennai; 2012.
2. Sweetman SC. Martindale–The Complete Drug Reference 36 th ed.(2009). Pharmaceutical Press, London;
3. Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. Pharm Sci Technolo Today. 2000; 3(6): 198–204.
4. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. Aaps Pharm SciTech. 2005; 6(3): E372–90.
5. Ulfa M, Husna NA. A case report of generalized tetanus in a 42-year-old man with dental infection. J Basic Clin Physiol Pharmacol [Internet]. 2020; 30(6). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077390988&doi=10.1515%2Fjbcpp-2019-0243&partnerID=40&md5=02e03cb89b71c9674bc3df09b2affc76
6. Wise DL. Handbook of Pharmaceutical Controlled Release Technology. CRC Press; 2000.
7. Shah SH, Patel JK, Patel N V. Stomach specific floating drug delivery system: A review. Int J Pharm Tech Res. 2009;1(3): 623–33.
8. Dirani D, Suharjono, Sedana M, Wahyuni S, Ardianto C, Alderman C. Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma. J Basic Clin Physiol Pharmacol [Internet]. 2020;30(6). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078359836&doi=10.1515%2Fjbcpp-2019-0336&partnerID=40&md5=a0d9e07d0af19b3d9eb706dd0fa06b5c
9. Patel MP, Patel J, Patel R, Patel K. Effect of formulation variables on the development of novel controlled release floating matrix tablets of cefixime. Int J Drug Deliv. 2011;3(3): 525.
10. Khan AD, Bajpai M. Floating drug delivery system: an overview. Int J Pharm Tech Res. 2010;2(4): 2497–505.
11. Mahendra YA, Yulistiani, Puspitasari D. Treatment strategy for pediatric patients with Kawasaki disease in Tertiary referral hospitals East Java Indonesia: A retrospective study. J Glob Pharma Technol [Internet]. 2019;11(4):153–61. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071197295&partnerID=40&md5=28ce1dbdd01beec8389494f974583398
12. Dehghan M, Kha F. Gastroretentive drug delivery systems: A patent perspective. Int J Heal Res. 2009; 2(1).
13. Moes AJ. Gastric retention systems for oral drug delivery. Bus Brief Pharmatech. 2003; 157–9.
14. Dow T. Using methocel cellulose ethers for controlled release of drugs in hydrophilic matrix systems. Midl Dow Chem Co. 2000; 1–36.
15. Singh N, Tiwari D. International Journal Of Pharma And Integrated Medicine.
16. Patel N, Nagesh C, Chandrashekhar S, Jinal P, Devdatt J. Floating drug delivery system: An innovative acceptable approach in gastroretentive drug delivery. Res J Pharm Dos Forms Technol. 2012;4(2): 93–103.
17. Organization WH. Index of Pharmacopoeias. Geneva: World Health Organization; 2002.
18. Chandira M, Chandramohan D, Chiranjib BJ, Kumar KPS. Design and characterisation of sustain release gastro retentive floating tablets of Diltiazem Hydrochloride. Sch Res Libr. 2009;1(2): 25–38.
19. Sakarkar DM, Kshirsagar R V, Deshbhratar RM. Studies on formulation and in vitro evaluation of gastroretentive drug delivery system of carbamazepine. Int J Chem Tech Res. 2010;2: 108–13.
20. Rahman MM, Roy S, Das SC, Jha MK, Begum T, Ahsan MQ, et al. Evaluation of various grades of hydroxypropylmethylcellulose matrix systems as oral sustained release drug delivery systems. J Pharm Sci Res. 2011;3(1): 930.
21. Roni MA, Kibria G, Jalil Rul. In vitro studies of controlled release alfuzosin matrix tablets prepared with ethylcellulose and hydroxypropyl methylcellulose. 2009.